This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
=== 2000-present === In 2000, the company opened a central laboratory in Singapore, building on clinical-development services formed in Singapore in 1996. In 2013, it expanded the capacity of the laboratory by 50%. In March 2001, the company sold Covance Pharmaceutical Packaging Services to Fisher Scientific for $137.5 million. In August 2005, it acquired GFI Clinical Services, an 80-bed clinical pharmacology business, from West Pharmaceutical Services for $5.7 million. In April 2006, the company acquired eight early phase clinical pharmacology sites from Radiant Research for $65 million. In June 2006, it acquired Signet Laboratories, a provider of monoclonal antibodies used in the research of cancer, infectious disease, and neurodegenerative disease, for $8.95 million. In 2007, the company opened a laboratory in Shanghai, China. In 2019, it opened a research and development center in Shanghai. In August 2008, the company acquired a campus in Greenfield, Indiana from Eli Lilly and Company and executed a 10-year service drug development service agreement with Lilly. In December 2008, the company acquired a minority equity stake in Caprion Proteomics, a provider of proteomics-based services to the pharmaceutical industry. The company was acquired by Chicago Growth Partners in July 2012. In 2009, the company acquired the Gene Expression Laboratory from Merck & Co. and entered into a five-year, $145 million contract to provide Merck with genomic analysis services.
The Malaysian Armed Forces has three branches: the Malaysian Army, Royal Malaysian Navy and the Royal Malaysian Air Force. There is no conscription, and the required age for voluntary military service is 18. The military uses 1.5% of the country's GDP, and employs 1.23% of Malaysia's manpower. Malaysian peacekeeping forces of MALBATT have contributed to many U.N. peacekeeping missions, such as in Congo, Iran–Iraq, Namibia, Cambodia, Bosnia and Herzegovina, Somalia, Kosovo, East Timor, and Lebanon. The Five Power Defence Arrangements is a regional security initiative that has been in place for almost 40 years. It involves joint military exercises held among Malaysia, Singapore, Australia, New Zealand, and the United Kingdom. Joint exercises and war games have also been held with Brunei, China, India, Indonesia, Japan, and the United States. Malaysia, Philippines, Thailand, and Vietnam have agreed to host joint security force exercises to secure their maritime border and tackle issues such as illegal immigration, piracy, and smuggling. Previously there were fears that extremist militant activities in the Muslim areas of the southern Philippines and southern Thailand would spill over into Malaysia. Because of this, Malaysia began to increase its border security.
Jennifer Phang ( PONG) is an American filmmaker (writer, director, producer), most known for her feature films Advantageous (2015) and Half-Life (2008). Advantageous premiered at the 2015 Sundance Film Festival, winning a Special Jury Award for Collaborative Vision, and was based on her award-winning short film of the same name. Half-Life premiered at the 2008 Sundance Film Festival and won "Best Film" awards at a number of film festivals including the Gen Art Film Festival, the San Francisco International Asian American Film Festival (now known as CAAMFest) as well as an "Emerging Director Award" at the Asian American International Film Festival.
Some of the earliest Israeli military efforts in March 2026 targeted the organization's supply of gold and foreign currency, as well as branches of the Al-Qard Al-Hasan Association, a non-profit financial institution that has been described as being "Hezbollah's bank in Lebanon". Money changing offices and gas stations were also struck, all as part of an effort to squeeze the organization's sources of funding. With the overland route through Syria cutoff in the wake of the Fall of the Assad regime in December 2024, Iranian funding efforts shifted to Beirut–Rafic Hariri International Airport, where Hezbollah influence allowed arms and cash to flow through. Under pressure from the United States, the Lebanese government blocked flights from Iran and took over security control of the airport. The Banque du Liban implemented controls that limited the ability of Hezbollah to accept international money transfers; restrictions were placed on connections between Lebanon's formal banking system and Al-Qard al-Hassan. To bypass these constraints, the hawala system had been used to send $1 billion in Iranian funds in 2025 via a network of broker transfers that passed through Iraq, Turkey and the United Arab Emirates, though sanctions have been placed on these brokers by the United States Department of the Treasury.
Sources: en.wikipedia.org
== Book references == Various (2002). Lide, David R. (ed.). Handbook of Chemistry & Physics (88th ed.). CRC. ISBN 978-0-8493-0486-6. OCLC 179976746. Archived from the original on 2017-07-24. Retrieved 2008-05-23.
=== Approval overview === Since 1996, seven novel insulin analogues have been approved. Three short-acting and four long-acting analogues have been made, while one short-acting lispro modification has been produced. Since 2021, three insulin biosimilars have been approved, two of which are long-acting and one of which is short-acting.
=== 13-31 August 2008 === An anonymous U.S. functionary said: "Saakashvili had always told us he could not stand by while Georgian villages were being shelled, and we always knew this was a point of pressure. We always told him that he should not give in to the kind of provocations we knew the Russians were capable of." In August 2008, Modest Kolerov, former head of the Department for international and cultural ties with foreign countries of the President's Office, admitted that the Kremlin had "a clear plan of action in the case of a conflict", and "the expediency with which the military operation was executed confirms that." Robert Gates, United States Secretary of Defense, said on August 14 that there had been clashes with the South Ossetian forces each August since 2004, but "This year it escalated very quickly and it seemed to me that Russians were prepared to take advantage of an opportunity and did so very aggressively." Zbigniew Brzezinski compared Russia's attack on Georgia to the Soviet attack on Finland and wrote that "Moscow was waiting for such an act to provide a pretext for the use of force." He suggested that Russia could attack Ukraine and other post-Soviet countries were not safe. Ralph Peters, a former military intelligence analyst, and several western diplomats (a western diplomat with contacts with the Georgians and a western mediator acquainted with Saakashvili) said that it was Russia who was provoking Georgia. It was reported that the United States had prevented Saakashvili from taking military action in Abkhazia in early May 2008.
=== Validation === Validation is intended to ensure a product, service, or system (or portion thereof, or set thereof) results in a product, service, or system (or portion thereof, or set thereof) that meets the operational needs of the user. For a new development flow or verification flow, validation procedures may involve modeling either flow and using simulations to predict faults or gaps that might lead to invalid or incomplete verification or development of a product, service, or system (or portion thereof, or set thereof). A set of validation requirements (as defined by the user), specifications, and regulations may then be used as a basis for qualifying a development flow or verification flow for a product, service, or system (or portion thereof, or set thereof). Additional validation procedures also include those that are designed specifically to ensure that modifications made to an existing qualified development flow or verification flow will have the effect of producing a product, service, or system (or portion thereof, or set thereof) that meets the initial design requirements, specifications, and regulations; these validations help to keep the flow qualified. It is a process of establishing evidence that provides a high degree of assurance that a product, service, or system accomplishes its intended requirements. This often involves acceptance of fitness for purpose with end users and other product stakeholders. This is often an external process.
== Function and effects == β-Endorphin function is said to be divided into two main categories: local function and global function. Global function of β-endorphin is related to decreasing bodily stress and maintaining homeostasis resulting in pain management, reward effects, and behavioral stability. β-Endorphin in global pathways diffuse to different parts of the body through cerebral spinal fluid in the spinal cord, allowing for β-endorphin release to affect the peripheral nervous system. Localized function of β-endorphin results in release of β-endorphin in different brain regions such as the amygdala or the hypothalamus. The two main methods by which β-endorphin is utilized in the body are peripheral hormonal action and neuroregulation. It is considered to act both as a neurotransmitter and a neuromodulator since it produces effects on distant targets that have increased stability and longevity when compared to other neurotransmitters. β-Endorphin and other enkephalins are often released with ACTH to modulate hormone system functioning. Neuroregulation by β-endorphin occurs through interference with the function of another neuropeptide, either by direct inhibition of neuropeptide release or induction of a signaling cascade that reduces a neuropeptide's effects.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.